Correlation Between Adaptimmune Therapeutics and Viking Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Adaptimmune Therapeutics and Viking Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Adaptimmune Therapeutics and Viking Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Adaptimmune Therapeutics Plc and Viking Therapeutics, you can compare the effects of market volatilities on Adaptimmune Therapeutics and Viking Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Adaptimmune Therapeutics with a short position of Viking Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Adaptimmune Therapeutics and Viking Therapeutics.

Diversification Opportunities for Adaptimmune Therapeutics and Viking Therapeutics

0.59
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Adaptimmune and Viking is 0.59. Overlapping area represents the amount of risk that can be diversified away by holding Adaptimmune Therapeutics Plc and Viking Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Viking Therapeutics and Adaptimmune Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Adaptimmune Therapeutics Plc are associated (or correlated) with Viking Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Viking Therapeutics has no effect on the direction of Adaptimmune Therapeutics i.e., Adaptimmune Therapeutics and Viking Therapeutics go up and down completely randomly.

Pair Corralation between Adaptimmune Therapeutics and Viking Therapeutics

Given the investment horizon of 90 days Adaptimmune Therapeutics Plc is expected to under-perform the Viking Therapeutics. In addition to that, Adaptimmune Therapeutics is 1.28 times more volatile than Viking Therapeutics. It trades about -0.22 of its total potential returns per unit of risk. Viking Therapeutics is currently generating about -0.12 per unit of volatility. If you would invest  3,977  in Viking Therapeutics on December 30, 2024 and sell it today you would lose (1,412) from holding Viking Therapeutics or give up 35.5% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Adaptimmune Therapeutics Plc  vs.  Viking Therapeutics

 Performance 
       Timeline  
Adaptimmune Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Adaptimmune Therapeutics Plc has generated negative risk-adjusted returns adding no value to investors with long positions. Even with conflicting performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.
Viking Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Viking Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Adaptimmune Therapeutics and Viking Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Adaptimmune Therapeutics and Viking Therapeutics

The main advantage of trading using opposite Adaptimmune Therapeutics and Viking Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Adaptimmune Therapeutics position performs unexpectedly, Viking Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viking Therapeutics will offset losses from the drop in Viking Therapeutics' long position.
The idea behind Adaptimmune Therapeutics Plc and Viking Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Other Complementary Tools

Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Fundamental Analysis
View fundamental data based on most recent published financial statements